Cytomegalovirus disintegrin-like peptides
AssigneeWisconsin Alumni Research Foundation
InventorsTeresa Compton, Adam L. Feire
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.
Claims38
A method of inhibiting viral infection of an animal host cell, the method comprising administering to the host cell an antiviral-effective amount of an active agent selected from the group consisting of a purified, integrin-binding gB disintegin-like peptide and a purified antibody that binds specifically to an integrin-binding, gB disintegrin-like peptide.
A pharmaceutical composition comprising an antiviral-effective amount of an active agent selected from the group consisting of a purified, integrin-binding gB disintegrin-like peptide, wherein the peptide is capable of inhibiting viral internalization into an animal host cell or an antiviral-effective amount and a purified antibody that binds specifically to an integrin-binding, gB disintegrin-like peptide.
A purified polypeptide comprising SEQ. ID. NOS:
- 1-5 or an amino acid sequence having at least 80% homology to SEQ. ID. NOS:
- 1-5.
A purified antibody that binds specifically to an integrin-binding, gB disintegrin-like peptide.
Dependencies are inferred from the claim text.